Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report
Open Access
- 21 April 2017
- journal article
- research article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 6 (6) , 886-892
Abstract
Salivary duct carcinoma is a highly aggressive disease with a poor prognosis. Surgical resection is currently the only curative treatment, as there is no effective systemic therapy for this malignancy. Recently, trastuzumab has been shown to exhibit therapeutic efficacy in the treatment of salivary duct carcinoma; similarly, molecularly targeted agents, such as cetuximab, are expected to be useful for salivary duct carcinoma treatment. We herein describe the case of a 56-year-old man diagnosed with salivary duct carcinoma in the left submandibular region, with ipsilateral multiple metastases to the neck lymph nodes. Radical resection of the tumor and submandibular gland with neck dissection were performed. One month after radical surgery, computed tomography (CT) scans indicated metastasis in the lower lobe of the left lung. CT-guided transthoracic fine-needle aspiration biopsy revealed a single metastasis and lung metastasectomy was immediately performed. The tumor cells of the primary lesion and those of the lung metastasis were immunohistochemically positive for epidermal growth factor receptor. One month later, multiple right lung metastases appeared, and the patient was treated with cisplatin/5-fluorouracil (5-FU) chemotherapy plus cetuximab, achieving a complete radiographic response. However, multiple lung metastases developed during adjuvant weekly cetuximab monotherapy. Subsequently, treatment with S-1 and weekly cetuximab was initiated, and the multiple lung metastases have been maintained as stable disease for 5 months. To the best of our knowledge, this is the first report of cetuximab use for the treatment of salivary duct carcinoma. Although cisplatin/5-FU chemotherapy plus cetuximab was efficacious in treating the lung metastasis, cetuximab monotherapy was insufficient for controlling tumor growth.Keywords
This publication has 35 references indexed in Scilit:
- Postoperative radiotherapy in patients with salivary duct carcinoma: clinical outcomes and prognostic factorsJournal of Radiation Research, 2013
- Genetic and Expression Analysis of HER-2 and EGFR Genes in Salivary Duct Carcinoma: Empirical and Therapeutic SignificanceClinical Cancer Research, 2010
- Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II studyOral Oncology, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Lung metastasis resection of adenoid cystic carcinoma of salivary glands☆European Journal of Cardio-Thoracic Surgery, 2008
- Prognostic values of pathologic findings and hypoxia markers in 21 patients with salivary duct carcinomaJournal of Surgical Oncology, 2008
- Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab‐based therapyHead & Neck, 2007
- Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapyHead & Neck, 2007
- Clinical and immunohistologic typing of salivary duct carcinomaCancer, 2005
- WHO International Histological Classification of Tumours Tentative Histological Classification of Salivary Gland TumoursPathology - Research and Practice, 1990